GlassScriptPhysician profile
Lindsay Capps
NPI 1154862910
$3,490.98
in general payments reported to CMS, 2019-2025
31 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $413 · 2023: $484 · 2024: $870 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.23 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $855.40 | 2023-2025 | |
| Astellas Pharma US INC | $517.36 | 2021-2025 | Veozah |
| Novo Nordisk INC | $413.95 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $270.50 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $163.04 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $149.56 | 2022 | |
| Urovant Sciences INC | $136.51 | 2021-2022 | |
| Amgen INC. | $112.93 | 2023-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $97.89 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $77.05 | 2024-2025 | Rexulti |
| Myovant Sciences INC. | $71.67 | 2021-2022 | |
| Lilly USA, LLC | $60.58 | 2024-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.38 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $57.21 | 2024-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $56.99 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $46.41 | 2025 | Auvelity, Symbravo |
| Lundbeck LLC | $38.87 | 2023 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.24 | 2024 | Xifaxan |
| Endo Pharmaceuticals INC. | $36.06 | 2021-2022 | |
| Shield Therapeutics INC | $33.07 | 2024 | |
| Dendreon Pharmaceuticals LLC | $31.88 | 2022 | |
| Antares Pharma, INC. | $28.44 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.44 | 2025 | Fanapt |
| Tolmar Pharmaceuticals, INC. | $23.10 | 2021 | |
| Corcept Therapeutics | $22.73 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $14.59 | 2023 | Trelegy Ellipta |
| Boston Scientific Corporation | $14.40 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.26 | 2025 | NP Thyroid 60 |
| Coloplast Corp | $13.04 | 2021 | |
| Abbott Laboratories | $11.94 | 2021 | |
| Travere Therapeutics, INC. | $2.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.